Alkem Labs Q2 Review: Dolat Capital Upgrades EPS Estimate For FY26-27 Maintaining Add - Check New Target Price
Alkem Laboratories Ltd.’s Q2 FY26 sales were above our estimates due to higher sales across segments. Ebitda came above estimates, mainly due to higher sales, lower than expected research and development and staff cost. Management expects low-double digit g…